Sudeep Pharma IPO
| DATE | GMP (GREY MARKET PREMIUM) | EXPECTED LISTING GAINS |
|---|---|---|
| 25-Nov-2025 | 85 | 2125 |
| 24-Nov-2025 | 113 | 2825 |
| 23-Nov-2025 | 122 | 3050 |
| 22-Nov-2025 | 115 | 2875 |
| 21-Nov-2025 | 115 | 2875 |
| 20-Nov-2025 | 130 | 3250 |
| 19-Nov-2025 | 120 | 3000 |
Sudeep Pharma IPO, a IPO of ₹895.00 Cr opens for subscription from November 21, 2025 to November 25, 2025. The IPO consists of ₹95.00 Cr fresh issue and ₹800.00 Cr offer for sale.
The face value of each share is 1, and the price band is set between 563.00-593.00 per share. The tentative listing date on the exchange (BSE, NSE) is November 28, 2025.
Sudeep Pharma IPO offers total 1,50,92,750 shares. Out of which 75,46,376 (50.00%) allocated to QIB, 30,18,553 (20.00%) allocated to QIB (Ex- Anchor), 22,63,912 (15.00%) allocated to NII 52,82,462 (35.00%) allocated to RII and 45,27,823 (30.00%) allocated to Anchor investors.
About Company
Sudeep Pharma is a technology-led manufacturer of excipients and specialty ingredients used in pharmaceutical, food, and nutrition industries. It develops products through in-house technologies such as encapsulation, spray drying, granulation, trituration, liposomal preparations, and blending. The company serves both domestic and international markets, including the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
It is one of the largest producers of food-grade iron phosphate with a total annual capacity of 65,579 MT as of December 31, 2024 (Source: F&S Report). One of its facilities is approved by the USFDA for manufacturing mineral-based ingredients. The company is also a leading exporter of mineral ingredients from India and one of the few global companies with CEP and written confirmation certification for calcium carbonate API in the European Union. It is among the early adopters of liposomal ingredient technology in India.
The business operates in two verticals:
1. Pharmaceutical, Food & Nutrition
This division focuses on refined, mineral-based ingredients such as calcium, zinc, iron, potassium, magnesium, sodium, and copper. These minerals support pharmaceutical formulations as excipients and are also used in foods, beverages, infant nutrition, and dietary supplements. The company also manufactures calcium carbonate as an API.
2. Specialty Ingredients
This segment, operated through subsidiary SNPL, produces technology-driven, application-specific ingredients like micronutrient premixes, encapsulated and liposomal ingredients, spray-dried and granulated minerals, and triturated blends. These products improve stability, bioavailability, texture, and nutritional value in functional foods, infant nutrition, supplements, and FMCG products.
The company has served over 1,100 customers worldwide, including major names such as Pfizer, Intas, Mankind, Merck, Aurobindo, Cadila, Micro Labs, and Danone. It generates a high share of revenue from repeat customers and maintains an average relationship of over seven years with its top clients.
With a presence in around 100 countries, the company operates regional offices in the United States, Europe, the UK, and Latin America, supported by third-party stocking partners. It runs three manufacturing facilities in Vadodara, Gujarat, equipped with advanced automation and multiple global certifications including USFDA, BRC, EXCiPACT, FSSC, WHO-GMP, ISO, HACCP, Kosher, and Halal.
The company also maintains a dedicated R&D center with a focus on particle engineering, nutrient bioavailability, shelf-life enhancement, and formulation solutions. Its R&D initiatives include developing solvent-free processes and innovative ingredient technologies.
Sudeep Pharma IPO Strengths
1.Market leadership with a diversified product portfolio in a high barrier industry
2.Distinguished global customer base with long-standing relationships with key customers
3.Well-equipped and regulatory compliant Manufacturing Facilities
4.Strong research and development capabilities
5.Experienced Promoters and senior management team